Skip navigation
Watchlist Sponsored By :

Current DateTime: 11:10:31 06 Jul 2009
LinksList Documentid: 24355697
  • Collection of Michael Jackson

      Earlier this year, Jackson sought to auction his personal items. Although it never came through, here's a look at what was almost sold.

  • Recession-Resistant US Cities

      Some cities have been hit much harder than others during the recession. Here are the metro areas faring the best.

  • How Much For A T-Bone Steak?

      From the cost of a T-bone steak to a monthly phone bill, the price for everyday items can vary dramatically across the country.


Current DateTime: 11:10:31 06 Jul 2009
LinksList Documentid: 24890560
  • Boom, Bust and Blame

      The inside story of the economic crisis that has gripped the entire world.

  • E3: Gaming's Cutting Edge

      North America's premier computer and video game trade show draws tens of thousands of professionals to experience the future of interactive entertainment.

  • The Fall of GM

      A look into the fall of General Motors as the automaker heads toward bankruptcy and an effective nationalization.

Schering-Plough Beats Earnings Forecasts By Wide Margin
By: CNBC.com | 19 Apr 2007 | 11:00 AM ET
Text Size

Schering-Plough [SGP  Loading...      ()   ] reported strong first-quarter results, surpassing consensus estimates by a wide margin due to strong sales of cholesterol drugs and allergy treatments.

Schering-Plough on Thursday morning announced first-quarter earnings growth of 55%, beating analysts' estimates on sharply higher sales of its prescription drugs, including two cholesterol fighters sold in partnership with Merck [MRK  Loading...      ()   ].

Profit rose 55% to $543 million, or 36 cents a share, from $350 million, or 24 cents a share, in the year-ago period.

Excluding one-time items, the Kenilworth, N.J.-based pharmaceutical company reported earnings of 42 cents a share. Analysts expected Schering-Plough to report 29 cents a share, according to Thomson Financial.

Sales in the period jumped 17% over last year to $3.0 billion before revenue from cholesterol drugs Vytorin and Zetia, which the drugmaker markets with Merck. Sales would have jumped 21% in the period including the co-marketed medicines.

Sales of allergy drugs Nasonex and Clarinex both came in above Wall Street estimates. The drugmaker also got a boost from arthritis treatment Remicade, which jumped 34% to $373 million in the first quarter. Schering-Plough sells Remicade outside of the U.S. and Japan under license from Johnson & Johnson [JNJ  Loading...      ()   ].

"This was largely a quality revenue-driven beat," said Tim Anderson, pharma analyst with Prudential Equity Group. "The 'whisper' was that Schering-Plough could beat by a significant margin, and they did. Other drug companies have also beat thus far this quarter, and those that have yet to report will probably beat as well."

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon


Current DateTime: 10:57:27 06 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 10:04:10 06 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 10:58:21 06 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:03:50 06 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters